knowledge -WSS

knowledge

author：entertainment 2025-09-29 21:22:49 - browse：3565

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

WSS

Roche subsidiary Foundation Medicine opens new headquarters

Why the world’s most expensive drug might be worth the price

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Study says nonprofit hospitals fall short in charity care spending

Supreme Court mifepristone arguments center on docs' right to sue

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

focus

knowledge

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

There's no autism epidemic. It's an autism diagnosis epidemic

After affirmative action ruling, medical educators look to 'holistic review'

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Bright Health sells Medicare Advantage business to Molina

In medicine, common shorthands can shortchange care

Apple is now the first public company to be valued at $3 trillion

Oprah kicked off a national conversation on obesity. Let's have it

23andMe had bad news about my health. I wish a person had delivered it

The UK government moves asylum

focus

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Scientists boost immune system in aging mice by making it youthful

Decaf coffee targeted by food safety group under obscure FDA rule

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

At least 12 people were injured in a blast at a port in northwest Turkey

In medicine, common shorthands can shortchange care

focus

explore

explore

knowledge